Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX

doi:10.4251/wjgo.122796

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 10

This Article

(13)

(12)

(0)

(10)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Oct 15, 2026; 18(10): 122796
Published online Oct 15, 2026. doi: 10.4251/wjgo.122796

Table 3 Univariate analysis of factors associated with treatment response

	MPR (n = 14)	Non-MPR (n = 25)	χ²/Z	P value
Sex			1.987	0.187
Male	11 (78.6)	14 (56.0)
Female	3 (21.4)	11 (44.0)
Age			0.223	0.733
≤ 60 years	4 (28.6)	9 (36.0)
> 60 years	10 (71.4)	16 (64.0)
Tumor differentiation			1.888	0.297
Poor	7 (50.0)	18 (64.1)
Moderate	7 (50.0)	7 (35.9)
Histological type			5.393	0.038
PC	2 (14.3)	13 (52.0)
Non-PC	12 (85.7)	12 (48.0)
Tumor location			1.988	0.370
Cardia	5 (35.7)	4 (16.0)
Gastric body	4 (28.6)	10 (40.0)
Gastric antrum	5 (35.7)	11 (44.0)
Lauren classification			2.889	0.108
Intestinal	9 (64.3)	9 (36.0)
Diffuse	5 (35.7)	16 (64.0)
cT			2.345	0.179
cT₃	8 (57.1)	8 (32.0)
cT₄	6 (42.9)	17 (68.0)
cN			10.242	0.003
cN₀	5 (35.7)	0 (0)
cN_1-3	9 (64.3)	25 (100.0)
pT			19.168	0.000
pT_0-2	13 (92.9)	5 (20.0)
pT_3-4	1 (7.1)	20 (80.0)
pT			13.374	0.000
pN₀	13 (92.9)	8 (32.0)
pN_1-3	1 (7.1)	17 (68.0)
Baseline CD3+ T lymphocytes (%)	66.05 (51.98, 79.23)	73.80 (70.30, 80.45)	-2.255	0.024
Baseline CD4+ T lymphocytes (%)	34.00 (32.60, 42.28)	42.70 (35.55, 48.15)	-2.108	0.035
Baseline CD8+ T lymphocytes (%)	29.05 (16.55, 36.53)	28.40 (21.15, 35.70)	-0.293	0.770
Baseline NLR	2.53 (1.84, 3.13)	2.30 (1.78, 3.41)	-0.088	0.930
Baseline PLR	189.27 (109.94, 209.08)	181.48 (132.58, 202.99)	-0.263	0.792
Baseline MLR	0.29 (0.22, 0.33)	0.27 (0.20, 0.35)	-0.234	0.815
Post-treatment CD3+ T lymphocytes (%)	78.15 (67.43, 83.53)	82.00 (73.00, 85.25)	-1.098	0.272
Post-treatment CD4+ T lymphocytes (%)	40.90 (31.60, 52.88)	43.40 (35.55, 50.10)	-0.381	0.703
Post-treatment CD8+ T lymphocytes (%)	31.00 (15.90, 42.50)	32.70 (23.40, 41.50)	-0.454	0.650
Post-treatment NLR	2.62 (2.31, 4.18)	2.68 (1.89, 3.96)	-0.351	0.725
Post-treatment PLR	185.07 (90.05, 194.27)	124.14 (89.37, 220.30)	-0.263	0.792
Post-treatment MLR	0.57 (0.42, 0.74)	0.39 (0.29, 0.54)	-2.196	0.028
ΔCD3+ T cell (%)	11.41 (5.37, 23.05)	5.06 (-4.09, 12.32)	-2.108	0.035
ΔCD4+ T cell (%)	5.96 (-8.10, 42.41)	2.16 (-8.62, 16.26)	-0.908	0.364
ΔCD8+ T cell (%)	15.79 (-6.19, 38.67)	9.44 (-1.57, 23.01)	-0.351	0.725
ΔNLR (%)	38.16 (-17.95, 64.18)	29.48 (-28.99, 55.18)	-0.716	0.447
ΔPLR (%)	-18.50 (-38.86, 10.81)	-30.63 (-47.68, -6.89)	-0.732	0.464
ΔMLR (%)	114.43 (50.51, 170.73)	57.53 (17.98, 89.64)	-2.576	0.010
ΔCD3+ T cell (%)	6.65 (3.05, 13.50)	3.70 (-3.10, 8.95)	-1.874	0.061
ΔCD4+ T cell (%)	1.70 (-3.10, 17.40)	1.00 (-4.15, 6.50)	-0.952	0.341
ΔCD8+ T cell (%)	3.30 (-1.85, 7.00)	2.90 (-0.45, 6.65)	-0.132	0.895
ΔNLR	0.68 (-0.54, 1.44)	0.65 (-0.61, 1.13)	-0.322	0.747
ΔPLR	-27.31 (-90.98, 10.66)	-51.53 (-117.17, -7.75)	0.878	0.380
ΔMLR	0.27 (0.14, 0.48)	0.11 (0.04, 0.22)	-2.752	0.006

NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; MLR: Monocyte-to-lymphocyte ratio; PC: Poorly cohesive gastric adenocarcinoma; MPR: Major pathological response.

Full Size Table

Citation: Wu Y, Xu MM, Wang GL, Du WD, Su XH. Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX. World J Gastrointest Oncol 2026; 18(10): 122796
URL: https://www.wjgnet.com/1948-5204/full/v18/i10/122796.htm
DOI: https://dx.doi.org/10.4251/wjgo.122796

Wu Y, Xu MM, Wang GL, Du WD, Su XH. Peripheral blood marker changes predict response and prognosis in locally advanced gastric cancer with neoadjuvant sintilimab plus XELOX. World J Gastrointest Oncol 2026; 18(10): 122796 [DOI: 10.4251/wjgo.122796]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.